CD8A and non-small cell lung carcinoma: Additionally, it has been demonstrated that exosomes derived from non‐small cell lung cancer (NSCLC) mediate resistance to anti‐PD1 therapy through the induction of CD8+ T‐cell depletion, highlighting a potential therapeutic target for treating NSCLC patients.117